Wound Healing Process as the Best Strategy to Save Cancer Patients
Keywords:
comparison, logistic, modified, naﶥ bayes, classification, viral load suppression., barriers, bangladesh, MPDSR, maternal deaths, neonatal deaths, enablers, scoping review, CCs; CSCs; cancer therapy; DIs; DHIs; differentiation therapy; wound healing.Abstract
The objective of this study is to develop effective strategies that can save cancer patients. Cancer therapy got to a bad start to rely on toxic chemicals to kill cancer cells (CCs) and to set up a rule on the reduction of tumor size to evaluate cancer drugs. These were mistakes committed by cancer establishments at a time we did not have whole knowledge of cancer to
result in horrendous cancer fatality, which is still on the way to increase. In 2022, President Biden urged health profession in to come up solutions to bring down cancer mortality by 50% in the following 25 years. Currently available cancer drugs, which are mostly based on the killing of CCs, are causing cancer mortality to increase by 5% annually. Health profession must get serious to develop strategies that can bring down cancer fatality. The best strategy to save cancer patients is to follow wound healing process, since cancer is caused due to wound unhealing.
References
M C Liau, J P Fruehauf (2022) Winning formulas to fulfill cancer moonshot. 1(1), 1-5.
M C Liau, L L Baker (2021) Cancer patients' lives matter. 6(5), 638-640.
M C Liau, C L Craig, L L Baker (2023) CDA formulations to fulfill cancer moonshot and to win the war on cancer. 2(2), 1-8.
M C Liau, C L Craig, L L Baker (2023) Restoration of chemo-surveillance as a top priority to save cancer patients. 6(2), 227-237.
M C Liau, J P Fruehauf (2023) Cancer moonshot: Moonshot as a magic code to guide successful solution of tough challenges such as cancer. 2(1), 1-5.
M C Liau, L L Baker (2020) Destruction promotes the proliferation of progenitor stem cells and cancer stem cells. Therefore, non-destruction is a better strategy for cancer therapy. 4(029). https://doi.org/10.24966/PPP-5649/100029
M C Liau, L L Baker (2021) Cancer arises as a consequence of wound not healing properly. Thus, perfection of wound healing must be the most appropriate strategy to win the war on cancer. 6(3), 584-586.
M C Liau, J H Kim, J P Fruehauf (2019) Destabilization of abnormal methylation enzymes. Natures' way to eradicate cancer stem cells. 2(5), 1-6. https://doi.org/10.33552/OJCAM.2019.02.000546
M C Liau, C L Craig, L L Baker (2023) A drastic change of cancer leaderships to save cancer patients. 61-69.
M C Liau, C L Craig (2022) Wound healing metabolites to heal cancer and unhealed wounds. 6(3), 8-20.
M C Liau, J P Fruehauf (2019) It has been half a century since President Nixon declared war on cancer: Destabilization of abnormal methylation enzymes has the blessing of the nature to win the war on cancer. 6(1), 538-539.
M C Liau, C L Craig, L L Baker (2023) Wound healing process as the most appropriate modality of cancer therapy. 11(1), 463-471.
R Virchow (1858) Die Cellular Pathologie in Ihrer Begrundung auf Physiologische und Pathologische Gewebelehve. 16, 440.
H F Dvorak (1986) Tumors: Wounds that do not heal. 315(26), 1650-1659.
L MacCarthy-Morrough, P Martin (2020) The hallmarks of cancer are also the hallmarks of wound healing. 13, 648.
MC Liau, GW Lin, RB Hurlbert (1977) Partial purification and characterization of tumor and liver S-adenosylmethionine synthetases. 37, 427-435.
MC Liau, CF Chang, BC Giovanella (1980) Demonstration of an altered S-adenosylmethionine synthetase in human malignant tumors xenografted into athymic nude mice. 64(5), 1071-1075.
MC Liau, P Zhuang, GCY Chiou (2010) Identification of the tumor factor of abnormal methylation enzymes as the catalytic subunit of telomerase. 7(2), 86-96.
MC Liau, M Szopa, B Burzynski, SR Burzynski (1989) Chemo-surveillance: A novel concept of the natural defense mechanism against cancer. 13(Suppl. 1), 72-82.
MC Liau, LL Baker (2021) The functionality of chemo-surveillance dictates the success of wound healing as well as cancer therapy. 7(2), 1-3.
MC Liau, CL Craig (2022) Chemo-surveillance as a natural mechanism to ensure perfection of wound healing to avoid cancer evolution and to cure cancer. 6.
MC Liau, SS Lee, SR Burzynski (1989) Hypomethylation of nucleic acids: A key to the induction of terminal differentiation. 2, 187-199.
MC Liau, CL Craig (2021) On the mechanism of wound healing, and the impact of wound on cancer evolution and cancer therapy. 5(3), 25-31.
MC Liau, CL Craig (2022) No scar as an indication of perfect wound healing, ugly scar as imperfect wound healing and cancer as failed wound healing. 12(1), 29-34.
MC Liau, CL Craig, LL Baker (2023) Wound unhealing as a grave issue of cancer. 6(1), 97-103.
Y Kudo, K Tateishi, K Yamamoto, S Yamamoto, Y Asaoka, H Ijichi (2012) Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. 103(4), 670-676.
GM Ficz, JG Gibben (2014) Loss of 5-hydroxym-ethylcytosine in cancer: Cause or consequence?. 104(5), 352-357.
MC Liau, CF Chang, FF Becker (1979) Alteration of S-adenosylmethionine synthetases during chemical hepatocarcinogenesis and in resulting carcinomas. 39, 2113-2119.
B N Kamparath, M C Liau, B Burzynski, S R Burzynski (1990) Protective effect of Antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin B1. 12((Suppl.)), 43-50.
A T V Ho, A R Palla, M R Blake, N D Yual, Y X Wang, K E G Magmusson, et al. (2017) Prostaglandin E2 is essential for efficacious skeletal muscle stem function, augmenting regeneration and strength. 114((26)), 6675-6684.
M C Liau, S S Lee, S R Burzynski (1988) Differentiation inducing components of Antineoplaston A5. (6/88), 9-26.
M C Liau, S S Lee, S R Burzynski (1990) Separation of active anticancer components of Antineoplaston A2, A3 and A5. 12((Suppl.)), 1-18.
M C Liau, P A Fruehauf, Z H Zheng, J P Fruehauf (2019) Development of synthetic cell differentiation agent formulations for the prevention and therapy of cancer via targeting cancer stem cells. 4, 1-15.
M C Liau, J H Kim, J P Fruehauf (2021) Arachidonic acid and its metabolites as the surveillance differentiation inducers to protect healthy people from becoming cancer patients. 4((1)), 7-10.
M C Liau, J H Kim, J P Fruehauf (2020) Destabilization of abnormal methylation enzymes to combat cancer: The nature's choice to win the war on cancer.
M C Liau, C P Liau, S R Burzynski (1992) Potentiation of induced terminal differentiation by phenyl-acetic acid and related chemicals. 5, 9-17.
M C Liau, L J Huang, J H Lee, S C Chen, S C Kuo (1998) Development of differentiation helper inducers for the differentiation therapy of cancer. 289-303.
M C Liau, C P Liau (2002) Methyltransferase inhibitors as excellent differentiation helper inducers for the differentiation therapy of cancer. 11, 166-168.
M C Liau, J H Kim, J P Fruehauf (2019) Potentiation of ATRA activity in HL-60 cells by targeting methylation enzymes. 3((1)), 9-17.
T Itkin, S Rafii (2017) Leukemia cells "gas up" leaky bone marrow blood vessels. 32((3)), 276-278.
D Passaro, A Di Tullio, A Abarrategi, K Rousault-Pierre, K Foster, L Ariza-McNaughton, et al. (2017) Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. 32((3)), 324-341.
M C Liau (2007) Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof.
Feng Feng, Qing Li, Chun Qian Ling, Yan Zhang, Feng Qin, Hui Wang (2005) Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma. 2(4), 706-716.
M C Liau, C L Craig, L L Liau (2023) Abnormal methylation enzymes as the most critical issue of cancer. 6(2), 168-176.
M C Liau, L L Baker (2021) Abnormal methylation enzymes as the bullseye of targeted cancer therapy. 7(4), 1-3.
M C Liau, C F Chang, G S Saunders, Y H Tsai (1981) S-Adenosylhomocysteine hydrolases as the primary target enzymes in androgen regulation of methylation complexes. 208(1), 261-272.
A C Racanelli, F B Turner, L Y Xie, S M Taylor, R G Moran (2008) A mouse gene that coordinates epigenetic controls and transcriptional interference to achieve tissue specific expression. 28(2), 836-848.
M C Liau, M E Hunt, R B Hurlbert (1976) Role of ribosomal RNA methylases in the regulation of ribosome production. 15(14), 3158-3164.
K A Bernstein, F Bleichert, J M Bean, F R Cross, S J Baserga (2007) Ribosome biogenesis is sensed at the start cell cycle check point. 18(3), 953-964.
Y Justilien, S A Ali, L Jamieson, N Yin, A D Cox, B J Ber (2017) ECT2-dependent rRNA synthesis is required for KRAS-TRP53-driven lung adenocarcinoma. 31(2), 256-269.
A Prudova, Z Bauman, A Braun, V Vitvitsky, S C Lu, R Banerjee (2006) S-Adenosylmethionine stabilizes cystathionine beta-synthase and modulates redox capacity. 103(17), 6489-6494.
P Chiba, C Wallner, E Kaizer (1988) S-Adenosylmethionine metabolism in HL-60 cells: Effect of cell cycle and differentiation. 971(1), 38-45.
M C Liau, L L Baker (2023) The impact of COVID-19 pandemic on cancer patients. 6(4), 13-17.
P J Williamson, A R Kruger, P J Reynolds, T J Hamling, D G Oscier (1994) Establishment of the incidence of myelodysplastic syndromes. 87(4), 743-745.
A Boula, M Voglarelis, S Giannouli, G Katrinakis, M Psylaki, C Pontikoglou, et al (2006) Effect of antitumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. 12(10), 3099-3108.
P S Woll, U Kjaliquist, O Chowdhury, H Doolittle, D C Wedge, S Thougjuea, et al (2014) Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. 25(6), 794-808.
J Ma (2007) Differentiation therapy of malignant tumor and leukemia. 480-486.
D V Santi, A Norment, C E Carret (1984) Covalent bond formation between a DNA-cytosine methyltransferase of DNA containing 5-azacytosine. 81(22), 6993-6997.
P Prassana, S Shack, V L Wilson, D Samid (1995) Phenylacetate in chemoprevention of 5aza-2'-deoxycytidine-induced carcinogenesis. 1(18), 865-871.
F Gaudet, J G Hodgson, A Eden, L Jackson-Grusby, J Dausman, J W Gray, et al (2003) Induction of tumor in mice by genomic hypomethylation. 300(5618), 489-492.
S S Palii, B O van Emburgh, U T Sankpal, K D Brown, K D Robertson (2008) DNA methylation inhibitor 5-aza-2'-deoxycytidine induces reversible DNA damage that is distinctly influenced by DNA-methyltransferase 1 and 3B. 28(2), 752-771.
T Kizietepe, T Hideshima, L Catley, N Raje, H Yasui, N Shiraishi, et al (2007) 5-Azacitidine, a methyltransferase inhibitor, induces ATR-mediated DNA-double strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicine and bortezomib against multiple myeloma cells. 6(6), 1718-1727.
Q Yang, F Wu, F Wang, K Cai, Y Zhang, Q Sun, et al (2019) Impact of DNA methyltransferase inhibitor-5-azacytidine on cardiac development of zebrafish in vivo and cardiomyocyte proliferation, apoptosis, and the homeostasis of gene expression in vitro. 120(10), 17459-17471.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.
